Zydus Launches Semaglutide Injection in an Innovative, Reusable Multi-Dose Pen Device in India
Mar 21, 2026
Ahmedabad (Gujarat) [India], March 21: Zydus Lifesciences Limited (including its subsidiaries, hereafter referred to as "Zydus"), an innovation-led global lifesciences company, has launched Semaglutide Injection under the brand names - SEMAGLYNTM, MASHEMATM and ALTERMETM, upon patent expiry in India. The Drug Controller General of India (DCGI) had earlier provided its approval for manufacturing and marketing Semaglutide injection for the treatment of both Type 2 Diabetes Mellitus and Obesity indications.1
Read More...
